I get it, but lets take the emotion out it for a m
Post# of 22465
(Total Views: 764)
Posted On: 01/18/2022 10:49:34 AM
Re: nucwarrant #21282
I get it, but lets take the emotion out it for a minute and look at this from a distance with actions we heard directly.
Negatives:
It is true, CEO Squires FAILED at a major part of duties making sure the filings were done on time.
Incompetence possibility, but it is also possible that the share structure was so screwed up by the L2 situation that no auditor would sign off.
But no matter what the reason QMC is where it is.
Positives
Working towards relisting:
Announced a shareholders meeting to raise AS,
had a shareholder meeting
Raised the AS
Finished filings for 2020
Working on filings for 2021
January 2021, Pasaca Capital put a valuation (not a market cap) on QMC at 30 million dollars
January 2021 signed a deal with Pasaca Capital for a MINIMUM OF 15 Million dollars to integrate the QMC HealthID into Innova products and in addition work to develop the next generation of diagnostic test for various disease states.
August 25, 2021 the company put out a PR, on what they were working to accomplish going forward,.
"We are currently developing 1) LFTs (lateral flow test kits) for TBI (traumatic brain injury, aka concussions), 2) a multiplex test that detects Covid-19, Flu and RSV (Respiratory Syncytial Virus), and 3) a vaccine validator (vac-check done October 14, 2021) to thwart counterfeit vaccines and validate vaccine efficacy."
"In addition, the Company has signed a term sheet with a Canada-based biotech company that has identified (Neurolytixs announced partnership) and has a patent-pending on several biomarker candidates that will be used to develop the TBI POCT. The term sheet is non-binding and we can provide no assurance that we will be able to reach definitive agreements on terms acceptable to the Company. We are in the process of negotiating the final terms that include the payment milestones required for QMC to design, develop, shepherd the FDA approval process, and produce the test kits."
Vac-check and Neurolytixs partnership seems to be a part of what was asked for in the Pasaca agreement and is a good indication that that agreement is still in place.
We were told in April 2020 by India that India was still in partnership with QMC,We were again reminded August 25 2021 that the India deal remains a active by the company.
Included in that update August 25,2021 was the company telling us Solterra, a wholly-owned subsidiary of QMC, long declared dead remains active, as well as other projects the company is pursuing.
Some will say Squires is lying to us, but for what purpose?. He couldn't use the update to sell shares. If lying why did he include the shelving of QMC HealthID.
With the company's announcement of Vac-check and Neurolytixs ANNOUNCEMENT of it's partnership with QMC the update seems to be truthful.
Objective opinion; Will QMC ever trade again, I haven't got a clue, but based on the evidence in front of us the odds look good that a bigger stronger company will emerge back on the trading floor.
Negatives:
It is true, CEO Squires FAILED at a major part of duties making sure the filings were done on time.
Incompetence possibility, but it is also possible that the share structure was so screwed up by the L2 situation that no auditor would sign off.
But no matter what the reason QMC is where it is.
Positives
Working towards relisting:
Announced a shareholders meeting to raise AS,
had a shareholder meeting
Raised the AS
Finished filings for 2020
Working on filings for 2021
January 2021, Pasaca Capital put a valuation (not a market cap) on QMC at 30 million dollars
January 2021 signed a deal with Pasaca Capital for a MINIMUM OF 15 Million dollars to integrate the QMC HealthID into Innova products and in addition work to develop the next generation of diagnostic test for various disease states.
August 25, 2021 the company put out a PR, on what they were working to accomplish going forward,.
"We are currently developing 1) LFTs (lateral flow test kits) for TBI (traumatic brain injury, aka concussions), 2) a multiplex test that detects Covid-19, Flu and RSV (Respiratory Syncytial Virus), and 3) a vaccine validator (vac-check done October 14, 2021) to thwart counterfeit vaccines and validate vaccine efficacy."
"In addition, the Company has signed a term sheet with a Canada-based biotech company that has identified (Neurolytixs announced partnership) and has a patent-pending on several biomarker candidates that will be used to develop the TBI POCT. The term sheet is non-binding and we can provide no assurance that we will be able to reach definitive agreements on terms acceptable to the Company. We are in the process of negotiating the final terms that include the payment milestones required for QMC to design, develop, shepherd the FDA approval process, and produce the test kits."
Vac-check and Neurolytixs partnership seems to be a part of what was asked for in the Pasaca agreement and is a good indication that that agreement is still in place.
We were told in April 2020 by India that India was still in partnership with QMC,We were again reminded August 25 2021 that the India deal remains a active by the company.
Included in that update August 25,2021 was the company telling us Solterra, a wholly-owned subsidiary of QMC, long declared dead remains active, as well as other projects the company is pursuing.
Some will say Squires is lying to us, but for what purpose?. He couldn't use the update to sell shares. If lying why did he include the shelving of QMC HealthID.
With the company's announcement of Vac-check and Neurolytixs ANNOUNCEMENT of it's partnership with QMC the update seems to be truthful.
Objective opinion; Will QMC ever trade again, I haven't got a clue, but based on the evidence in front of us the odds look good that a bigger stronger company will emerge back on the trading floor.
(1)
(0)